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ABSTRACT
Elucidating the relation between human milk fatty acids, extracellular vesicles, and infant
health outcomes in the first year of life
by Diana Claire Bickmore
For most infants, human milk is the recommended source of nutrition. Improved developmental
outcomes have been reported in infants that consume human milk compared to infant formula.
Essential fatty acids (EFAs) confer health benefits. However, EFAs cannot be synthesized by the
body, and therefore must be consumed in diet. Extracellular vesicles (EVs) are nanoparticles
containing a lipid bilayer membrane and are present in human milk. Methods of EV isolation
such as ultracentrifugation (UC) may not be feasible for the study of EVs in human milk due to
the need for large sample volume, which may not be available. The objectives of this research
were therefore to investigate i) if the concentration of essential fatty acids in milk correlated to
infant developmental outcomes reported by the Bayley Scales of Infant Development (BSID-III)
and ii) if an EV isolation method using a precipitation method could be optimized for isolation of
EVs in a low volume of human milk. Human milk samples were obtained two weeks postpartum (n=70), and corresponding developmental data was obtained. Total fatty acids from milk
samples were quantified by Gas Chromatography-Mass Spectrometry (GC-MS). Electron
microscopy, nanoparticle tracking analysis, and semi-quantitative antibody array were conducted
to confirm isolation of human milk EVs. Count, size, protein content, and fatty acid
quantification of EVs were also determined. Arachidonic acid was inversely correlated with
Cognitive Composite scores at 12 months of age (p<0.05). The EV isolation technique yielded
8.9 x 109 ± 1.1x 109 EV particles/mL of human milk, and meets the Minimal Information for
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Studies of Extracellular Vesicles (MISEV) guidelines. Validation of an EV isolation protocol for
small volumes of human milk will facilitate research in this growing area. It can be concluded
that bioactive components of human milk are related to infant development, and future research
on fatty acids and EVs and human milk is warranted to assist nutritional recommendations for
breastfeeding mothers and manufacturers of commercial infant formula.
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1. Bioactive Components in Human Milk: A literature review and
introduction to the present research
Introduction
In 2015 only about 25% of babies in the United States were exclusively breastfed for the
first 6 months of life. The American Academy of Pediatrics recommends that infants should be
exclusively breastfeed for the first 6 months of life (CDC, 2018). Because human milk is the
recommended source of nutrition for infants, a greater understanding of its composition is crucial
to public health. There is therefore a critical need to explore the associations between infant
health outcomes, and bioactive components in human milk. This may facilitate nutritional
recommendations for breastfeeding mothers in the perinatal period, and inform the nutritional
composition of commercial infant formulas made to mimic the biological properties of human
milk and human milk fortifiers designed to optimize human milk. The present study will define
infants as children younger than one year of age (WHO, 2013), and newborns as children under
one month of age.
Fatty acids in human milk have been linked to improved infant health and developmental
outcomes. The consumption of essential fatty acids (EFA) by infants, such as docosahexaenoic
acid (DHA) and eicosopentanoic acid (EPA) has been correlated to superior visual acuity and
cognitive development (Makrides, Simmer, Goggin, & Gibson, 1993), and infants consuming
infant formula fortified with DHA and arachidonic acid (ARA) scored closer to infants fed
human milk (Lien, Richard, & Hoffman, 2018). Although human milk is the recommended
source of nutrition for the first six months of life, the relation between bioactive compounds,
such as essential fatty acids present in human milk and standardized developmental outcomes in
the absence of confounding variables associated with breastfeeding remains unclear.
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Extracellular vesicles (EV) are a type of bioactive component present in human milk that
may confer health benefits to newborns and infants. EVs are produced by nearly every type of
mammalian cell for cell to cell communication (De la Torre Gomez, Goreham, Serra, Nann, &
Kussman, 2018). EVs are composed of proteins, nucleic acids, and lipids. Lipids and fatty acids
are crucial components of extracellular membranes, and specific lipids and fatty-acid containing
lipids such as sphingomyelin and cholesterol have been found in higher concentrations in EVs
compared to the cell from which it was derived (Llorente et al., 2013). EVs in human milk have
been found to mediate immune and inflammatory responses and the promotion of epithelial
growth in the intestine. (De la Torre Gomez et al., 2018; Hock et al., 2017b).
This gap in knowledge may exist partly due to the difficulty of isolating EVs. Although
ultracentrifugation (UC) is the “gold standard” technique for the isolation of EVs, it requires
sample volumes in excess of several mL, and may result in the co-isolation of contaminants like
albumins and immunoglobulins (Caradec et al., 2014). Using a large sample volume for isolation
of EVs from human milk is often not feasible, as the milk is needed to feed the infant, and
mothers may not lactate sufficient excess volumes to be collected for research. The necessity of
large sample volumes of human milk for research purposes relegates researchers to only studying
mature milk. This hinders the study of variation over i) early, transitional and mature milk
production periods, ii) course of lactation (fore vs. hind milk), and iii) time-of-day.
The overarching goals of this project were to correlate the fatty acid composition of
human milk and human milk EVs to infant health and development (Cognitive, Behavioral, and
Motor) outcomes reported by the Bayley Scales of Infant Development (BSID-III). It was
hypothesized that bioactive components in human milk are related to developmental outcomes in
infants. To investigate this hypothesis, essential fatty acids were correlated to BSID-III
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outcomes. Determining the relation between the fatty acid content of EVs in human milk and
infant developmental outcomes was not feasible due to the lack of a suitable EV isolation
method. Therefore, the second objective became to optimize an EV isolation method for low (<2
mL) volumes of human milk to facilitate the study of EV composition and infant health and
developmental outcomes in future research.

Review of Literature
Nutritional benefits of human milk
For most infants, human milk provides the best source of nutrition and benefits the health of both
mothers and infants, reducing risk for short and long-term health conditions include asthma,
obesity, Type II diabetes, ear and respiratory infections, and gastrointestinal infections (CDC,
2018). Infants consuming human milk benefit epidemiologically from protection against illness
and infection due to specific and non-specific immune factors found in human milk (Oddy,
2002); protective components in milk such as secretory IgA antibodies and lactoferrin confer
immunity against common infections to breastfed infants (Hanson et al., 2003). The benefits of
consuming human milk may also extend beyond infancy. (Wilson et al., 1998) investigated the
correlation between exclusive consumption of human milk in infancy and childhood respiratory
illness, growth, and body composition, and found that infants who were exclusively fed human
milk for 15 weeks (compared to infants partially fed human milk for 15 weeks and formula fed
infants) experienced lower incidences of respiratory illnesses and wheezing during childhood, as
well as lower percentages of body fat and weight, indicating less risk of childhood obesity.
Consumption of human milk has even been correlated with lower rates of AttentionDeficit/Hyperactivity Disorder (ADHD) in children (Mimouni-Bloch et al., 2013). Despite the
multitude of short and long-term benefits associated with consuming human milk, the majority of
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infants do not consume human milk exclusively for as long as recommended by the World
Health Organization and American Academy of Pediatrics, with only 1 in 4 exclusively breastfed
for 6 months (CDC, 2018).
Variability of fatty acid composition of human milk
Human milk is widely considered more nutritious for infants than infant formula.
Studying the composition of human milk can therefore help create more nutritious infant formula
products. The fatty acid composition of human milk was examined using gas-liquid
chromatography and spectrophotometry (Insull & Ahrens, 1959). It was found that human milk
fatty acids consisted of: oleic (29%), palmitic (21%), myristic (9%), linoleic (7 %), stearic (7 %),
lauric (7 %), isooleic (7 %), palmitoleic (2 %), and other species in minor quantities. More
recently, meta-analyses have compared the composition of human milk fatty acids at similar
points of lactation worldwide (Barreiro, Díaz-Bao, Cepeda, Regal, & Fente, 2018), and fatty
acids present in smaller amounts have been quantified. Comparing 21 studies of the fatty acid
composition of human milk worldwide to the composition of human milk in Galicia, Spain, it
was found that worldwide, fatty acid profiles of human milk were similar, with the exception of
several Asian countries (Barreiro et al., 2018). Women in Asian countries where consumption of
marine products is high had elevated levels of DHA in milk. While maternal diet is a well-known
factor that alters the fatty acid composition of human milk, other variables that may influence the
fatty acid composition of human milk have also been investigated. In a study of 71 Australian
infants exclusively consuming human milk, it was suggested that the average fat content was
independent of the gender of the infant, and that the mean fat content of milk was significantly
(p<0.001) related to the time of day, with the mean fat content of the milk collected in the day
and evening (42.8 ± 9.1 and 43.2 ± 9.1 g/L, respectively) being higher than the milk collected in
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the morning and at night (37.1 ± 10.1 and 37.2 ± 10.3 g/L, respectively), which was likely due to
more milk being removed during the day and evening from feedings (Kent et al., 2006).
Essential fatty acids, and fatty acid desaturase
Omega-3 and omega-6 are classes of polyunsaturated fatty acids (PUFAs) consisting of at
least one cis-double bond (Food and Nutrition Board, 2002). In omega-6 fatty acids, the last
double bond is situated between the sixth and seventh carbon atom from the methyl end of the
fatty acid, and in omega-3 fatty acids, the last double bond is situated between the third and
fourth carbon atom from the methyl end of the fatty acid. The two precursors to long chain
polyunsaturated fatty acids (LC-UPUFAs) are linoleic acid (LA) and alpha-linolenic acid (ALA)
(Figure 1-1). LA (18:2n-6) and ALA (18:3n-3) have no known biological activity. LA and ALA
are essential because they cannot be synthesized by humans, meaning they must be consumed in
diet to prevent nutritional deficiency. Although humans are able to synthesize saturated fatty
acids and monounsaturated fatty acids from acetyl coenzymeA, humans are not able to
synthesize EFA because they do not have the enzymes needed to add a cis-double bond at the n3 or n-6 position. Long-chain omega-3 and omega-3 products docosahexaeonoic acid (DHA) and
arachidonic acid (AA) respectively can be synthesized from their ALA and LA precursors
respectively (Tressou, Buaud, Simon, Pasteau, & Guesnet, 2019), albeit with very low
efficiency.

a.)
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b.)

Figure 1-1. Chemical structures of linoleic acid (a) and alpha-linolenic acid (b), the two precursor

essential fatty acids. Created with ChemDraw 18.

Deficiencies in EFA have been associated with decreased growth in children and infants,
greater susceptibility to infections, and slower wound healing (Jeppesen, Høy, & Mortensen,
1998). Omega-3 and omega-6 PUFAs are structural components of plasma membranes, and can
influence membrane properties including fluidity, permeability, and activity of membrane-bound
enzymes (Nakamura & Nara, 2004). However, there is inter-individual variability in the
metabolism of fatty acids. The FADS-1 and FADS-2 enzymes modulate the synthesis of ARA
and DHA from LA and ALA. Polymorphisms in the FADS-1 and FADS-2 genes encode the
enzymes that alter the production and thus concentration of LC-PUFAs (Lattka, Illig, Heinrich,
& Koletzko, 2009) for consumption in human milk. Therefore, fatty acid content of infants and
newborns consuming human milk as well as maternal FADS genotype may impact health
outcomes of newborns and infants.
Fatty acids in infant formula and human milk
DHA and ARA are conditionally essential fatty acids since (Larque, Demmelmair, &
Koletzko, 2002) infants are able to synthesize DHA from ALA and ARA from LA. However,
infants are not able to synthesize sufficient amounts to maintain cellular and plasma DHA
concentrations without consuming additional DHA from diet (Larque et al., 2002). When infants
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consume pre-formed ARA and DHA in human milk, they exhibit higher plasma and tissue
phospholipid levels than babies that consume infant formula. It has therefore been proposed that
infant formulas be fortified with DHA so the cellular and plasma DHA levels of formula fedinfants could reach those of infants consuming human milk (Larque et al, 2002). ARA is
typically less varied in human milk than DHA (Carlson & Colombo, 2016).
Like DHA, ARA has been associated with infant growth and development. Higher levels
of erythrocyte phospholipid ARA concentrations in infants were correlated to increased growth
(weight and length) at 2, 4, 6.5, and 9 months of age (Carlson, Werkman, Peeples, Cooke, &
Tolley, 1993), and infants consuming human milk and infants consuming formula supplemented
with DHA and ARA were found to have better visual acuity at 2 months of age (Carlson, Ford,
Werkman, Peeples, & Koo, 1996). Although infants have the ability to synthesize ARA and
DHA from the precursors, infants consuming human milk with lower concentrations of ARA and
DHA, and infants consuming infant formula that is not fortified with ARA and DHA may still
experience deleterious health impacts due to the inherent inefficiency of ARA and DHA
conversion. The negative implications associated with ARA and DHA deficiency during infancy
warrant further consideration for infants fed human milk and formula.
Infant health in relation to maternal diet
The milk composition of indigenous women in Bolivia was examined. Milk samples of
Bolivian women were compared to samples from women in the United States at corresponding
lactational stages to compare the fatty acids (M. Martin et al., 2012). It was found that the
percentages of ARA, DHA, total n-3 and total n-6 LCPUFAs were significantly greater in the
indigenous women. This was likely due to their traditional diet including higher consumption of
wild game, freshwater fish, and a limited consumption of processed foods and oil. These findings
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have important implications for maternal nutrition. If the fatty acid composition of human milk
can be easily altered by diet, women can consume diets that would result in a favorable fatty acid
composition of milk. Alternatively, human milk fortifiers could be utilized to compensate for
dietary deficiencies.
Maternal nutrition is important for breastfeeding mothers, since maternal diet impacts the
composition of human milk. Perinatal nutrition has acute and chronic impacts on immunity and
metabolism in newborns, babies, infants and children (De la Torre Gomez et al., 2018). Maternal
protein intake is positively correlated with lipid concentration of human milk after 16 weeks
postpartum (Nommsen, Lovelady, Heinig, Lönnerdal, & Dewey, 1991). Additionally, in a
randomized control trial in which mothers were assigned to either a placebo or DHAsupplemented group, the DHA concentrations in the milk of the supplemented group
significantly (p<0.05) increased (Valentine et al., 2012) over time relative to the placebo group.
This evidence reaffirms that the presence of specific fatty acids in maternal diet alters the fatty
acid composition of human milk, and that maternal nutrition impacts the composition of human
milk.

Standardized health and behavioral tests for infants
The Bayley Scales of Infant Development
The BSID-III is an individually administered test to measure developmental functioning of
infants and toddlers. The test identifies developmental delay and accelerated developmental
trajectories and tracks a child’s developmental progress. The BSID-III can be administered to
children between 1 and 42 months of age. The BSID-III is comprised of Cognitive, Language,
Motor, Social-Emotional, and Adaptive Behavior Scales (Bayley, 2006), and includes activities
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such as pretend play, novelty preference, habituation, and number ordering. Based on the
composite scores in the various scales, the test identifies signs of developmental delay and
advanced developmental trajectories. To that end, the primary goal of the Bayley-III is simply to
identify whether or not children are experiencing developmental delay, not to provide a specific
diagnosis for a disorder (Albers & Grieve, 2007). The BSID-III was designed to be simpler with
respect to the administration of the test. Scoring is less ambiguous than in previous editions, as
the only possible scores recorded by examiners trained in developmental interpretation and
assessment are 0 and 1 (no credit and credit respectively). Typically a caregiver remains present
in the room during administration of the BSID-III to ensure accurate representations of the
infant’s optimal performance and prevent negative behavioral reactions that may stem from
separation. The chronological age of the child being examined corresponds to a designated
starting point for Cognitive, Motor, and Language scales, and scoring is discontinued if five
consecutive items are given no credit (Albers & Grieve, 2007).
Of the five scales that comprise the BSID-III, the following three are administered by the
clinician: Cognitive, Motor, and Language. Specifically, the Cognitive scale assesses play skills,
information processing related to attention to novelty and memory, and problem-solving,
counting, and numerical skills. The Language Scale assesses receptive and expressive language
to examine communication skills, and the Motor Scale examines both Fine and Gross Motor
skills (Bayley, 2006).
Standardized health and developmental outcomes in relation to human milk
Human milk is considered the optimal source of infant nutrition for newborns. However,
there is a lack of information correlating standardized measures of health and developmental
outcomes to the composition of human milk. There is also a lack of information correlating
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specific bioactive components of human milk, such as fatty acids, to these outcomes. Although
human milk consumption has been correlated with increased cognitive functioning in infants,
many of the correlations found between consumption of human milk and superior cognitive
functioning may be confounded by other factors associated with breastfeeding such as maternal
socioeconomic class and intelligence quotient (IQ) (Walfisch, Sermer, Cressman, & Koren,
2013).
Although specific fatty acids, such as DHA and AA, have been associated with cognitive
benefits when used as ingredients in infant formulas (Larque et al., 2002), the benefits associated
with bioactive components of human milk are also often limited by confounding factors. Various
experiments have only been designed to correlate newborns fed human milk to those fed infant
formula with particular health and behavioral outcomes, meaning the actual composition of the
human milk that breastfed infants consume is not taken into account.
In a study of 771 low birthweight infants, babies whose mothers provided human milk
instead of formula exhibited greater mean Bayley developmental index scores even after
adjusting for demographic and perinatal factors (Morley, Cole, Powell, & Lucas, 1988).
Likewise, after adjusting for the several confounding factors, including maternal age,
intelligence, education, and smoking status during pregnancy, it was found that infants fed
human milk scored higher on the Bayley mental development index (MDI) at 13 months of age if
they had been fed human milk for six months after birth instead of fewer than three months
(Angelsen, Vik, Jacobsen, & Bakketeig, 2001). The present study will build upon the prior
knowledge correlating consumption of human milk to particular health and behavior outcomes
by correlating specific bioactive components of human milk, such as fatty acids, instead of
human milk as a whole, to health and behavioral outcomes.
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The BSID-III was used to compare infants fed formula exclusively and infants fed both
human milk and formula, as well as infants fed human milk exclusively in bottles versus human
milk directly from the breast (Pang et al., 2019). It was found that infants who were bottle-fed
human milk exhibited significantly better Cognitive scores on the BSID-III at 2 years than
infants only fed infant formula. Interestingly, compared to the infants who were bottle-fed
human milk, infants who consumed human milk by breastfeeding achieved higher scores on
several memory tasks. Thus, confounding factors such as the discrepancy in the BSID-III scores
between infants that were breastfed and bottle-fed human milk emphasize the importance of
relating specific components found in human milk to test outcomes, and highlight that results
from infants consuming human milk administered differently should not be considered
analogous.
Description and significance of extracellular vesicles
EVs were first described in 1983 as vesicles secreted by red blood cells, but became of
interest to immunologists when it was discovered (Raposo et al., 1996) that cells of the immune
system could secrete exosomes when multivesicular bodies (MVBs) fused with the plasma
membrane (Bobrie, Colombo, Raposo, & Théry, 2011). The term “exosome” was proposed to
refer to the extracellular vesicles that originated from intraendosomal regions of mammalian
cells (Johnstone, Adam, Hammond, Orr, & Turbide 1987).
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Figure 1-2. Formation and release of exosomes from cells. Figure (Skotland, Sandvig, &
Llorente, 2017) reprinted from the PhD degree of Santosh Phuyal, University of Oslo.
Exosomes are membrane vesicles enclosed in a lipid bilayer. These nanoparticles are
released by most mammalian cell for intercellular communication, and are unique to the cell in
which they originate (De la Torre Gomez et al., 2018). EVs circulate in human biological fluids
such as blood, urine, saliva, and human milk (De la Torre Gomez et al., 2018). There are three
steps in exosome biogenesis: biogenesis of MVBs, the transport of MVBs to the plasma
membrane, and the fusion of the MVBs with the plasma membrane (Figure 1-2), which releases
the intraluminal vesicles from the MVBs. Exosomes are the smallest of the three types of EVs,
the other two being microvesicles and apoptotic bodies (T Skotland et al., 2017).
The function of EVs was further emphasized due to their touted role in cancer
progression. In lung cancer, platelet derived microvesicles transferred an integrin (CD41) to
numerous lung cancer lines, eliciting the highest response in highly metastatic cells, which
indicated the significance of extracellular vesicles in disease pathology (Janowska-Wieczorek et
al., 2005). EVs contain microRNA and messengerRNA. When mouse EV-derived RNA was
transferred to human mast cells, new mouse proteins were found in the recipient cells, indicating
12

that the transferred mRNA was able to be translated after entering a new cell (Valadi et al.,
2007). Bovine milk derived EVs were used for drug delivery because EVs from bovine milk can
be obtained more cost-effectively and on a larger scale (Munagala, Aquil, Jeyabalan, & Gupta,
2016). Bovine milk EVs were also found to have cross-species tolerance; when mice possessing
human lung cancer (A549) xenografts were treated with the cancer drug Withaferin A (WFA) as
free-WFA or exo-WFA (drug-loaded EVs), the exo-WFA exhibited a significantly greater tumor
inhibitory effect (46% vs 23%) than the free WFA (Munagala et al., 2016).
Given the public health importance of cancer and drug research, the study of EVs in other
fields has been neglected. For example, (T Skotland et al., 2017) analyzed approximately 280
lipid species in the metastatic prostate cancer cell line PC-3 (Llorente et al., 2013) and stated that
to their knowledge, the only study providing quantitative data for both the parent cell and
exosomal lipid composition of more than just a few lipid species was their own, which still
holds true. There is therefore a general gap in knowledge regarding the application of EVs to
other fields such as nutrition. There is also limited knowledge on fatty acid constituents of
extracellular vesicles, which may be involved in cellular processes such as EV release and
formation.
Lipids and fatty acids in extracellular vesicles
Lipids in the plasma membrane may influence the formation and release of the EVs
during the biogenesis of EVs. Compared to the cell from which it is derived, lipids such as
cholesterol and sphingomyelin are enriched in EVs (Llorente et al., 2013). The intraluminal
vesicles of multivesicular endosomes are sorted into lysosomes for degradation of cargo, or
secreted as EVs (Trajkovic et al., 2008), a process that is dependent on the composition of lipids.
It was found that the transfer of exosome-associated domains into the lumen of the endosome
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required the sphingolipid ceramide, which implicated lipids in the formation and subsequent
communication functions of EVs (Trajkovic et al., 2008). EV synthesis, release and transport
occur in a highly regulated manner and thus it is plausible that alteration of lipids composition of
EV may alter function.
A study quantifying over 217 lipids in the EVs of PC-3 cells showed differences in the
relative proportion of lipids of EVs compared to the cells of origin (Llorente et al., 2013). The
total lipid concentration in protein was 94.2 ± 6.8 in PC-3 cells and 790.7 ± 68.5 in nmol/mg in
EVs, indicating a greater-than 8-fold enrichment of lipids into EVs per mg protein (Llorente et
al., 2013). Additionally, it was discovered that the relative proportions of glycosphingolipids,
cholesterol, sphingomyelin (SM), and phosphatidylserine (PS), was over 15 times higher in the
EVs than in the cell of origin (Llorente et al., 2013). The membrane of EVs is highly ordered,
and the high composition of glycosphingolipids in EVs likely confers EVs with stability in
extracellular environments, which is essential for their role in cell-to-cell communication. Lipids
in EVs have also been associated with biogenesis and communication due to the presence of
lipid raft associated proteins such as flotillin-1; lipid rafts are areas of the plasma membrane rich
in cholesterol and glycosphingolipids (de Gassart, Geminard, Fevrier, Raposo, & Vidal, 2003).
The tetraspanins CD9 and CD81 have also been found to be physically and functionally linked
with cholesterol; tetraspanins are believed to form a tetraspanin “web” of molecular interaction.
Tetraspanin/tetraspanin complexes were precipitated using digitonin, a cholesterol precipitating
reagent (Charrin et al., 2003). Due to the interaction of tetraspanin with cholesterol, it was
postulated that tetraspanins in EVs may be attributed to the association with lipid rafts
(Brzozowski et al., 2018).
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Inconsistency in methods of EV isolation and analysis have hindered the acquisition of
knowledge pertinent to the significance of the lipid composition of EVs (T Skotland et al., 2017).
Results from the different techniques are dependent on not just the method used, but also the
purity of the samples being analyzed (T Skotland et al., 2017). Additionally, lipids present in
EVs isolated from different biofluids vary, including EVs from the same biofluid in healthy
controls and diseased patients (Table 1-1). Consistent isolation and characterization methods for
EVs and constituents of EVs from different biofluids, including complex matrices such as human
milk, are therefore necessary to understand the specific function of lipid compositions that have
been observed in lipid bilayers of EVs. Although the present study does not explore the
composition of fatty acid-enriched fractions of EVs, the validation of an isolation method for EV
isolation in human milk will facilitate such future studies on the structure and functional
significance of EVs in human milk.
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Table 1-1. Summary of lipids and fatty acids in EVs in the literature.
Origin of
EVs

Type of Lipid(s)
Studied

Focus of Study

Key Findings and Conclusions

Citations

Urine

107 lipid species
were quantified
using mass
spectrometry
quantitative
lipidomic analysis.
Lipid species refer
to lipid molecules
with different fatty
acyl groups.

Exosomes are noninvasive biomarkers
for cancer.
The use of lipids in
urinary exosomes of
prostate cancer
patients was
investigated.

Of the 107 lipid species, 36 of the
most common lipid species were
further analyzed, 9 of which
significantly differed between
cancer patients and healthy controls.
Lipids in urinary exosomes may be
useful as biomarkers for prostate
cancer since the high patient:
control ratio of specific lipids such
as phosphatidylserine distinguished
the cancer patients from controls.

(T. Skotland
et al., 2017)

Phosphatidylserine
and
lactosylceramide
were significantly
higher in cancer
patients compared
to healthy
controls.
Exosomes
secreted by a
parasite
internalized

Plasmalogens,
other
glycerophospholip
ids, cholesterol,

Since lipids are key
constituents of
exosomes given that
the lipid bilayer of

Plasmalogens and other classes of
glycerophospholipids were enriched
9 to 62 fold, and a comparative lack
of cholesterol and SM in the
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(Simbari,
2016)

by mouse
epithelial
cells

Skeletal
muscle
derived
microvesicles
(SkMV)
collected
from plasma

and sphingomyelin exosomes is exposed
(SM).
to the environment,
the composition of
parasite-secreted EVs
were compared to
exosomes secreted by
a murine host. Ultraperformance liquid
chromatography �
tandem mass
spectrometry (UPLCMS/MS) was used for
lipid analysis.
Long-chain fatty
Investigate whether
acids (LCFA)
or not acute exercise
(a single bout)
influences SkMV
expressing LCFA
transport proteins
CD36 (SR-B2) and
FATP4 in obese
males with type II
diabetes and obese
male controls.

parasitic exosomes was observed
compared to the murine exosomes.
Analyses of exosomal membrane
dynamics indicated the membrane
of the nematode was more rigid.
The parasite may maintain rigidity
of the exosomal membrane from
increased plasmalogens compared to
other lipids, plasmalogens are
highly prevalent in some EVs.
Nielsen et al. (2019) found a
positive correlation between
SKMVs carrying CD36 and
performance of acute exercise only
in males with type II diabetes. The
authors conclude that studying
LCFA transport protein released by
EVs in “real-time” could be key to
understanding LCFA uptake in
subjects that have impaired glucose
metabolism.
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(Nielsen et
al., 2019)

Isolation of EVs, quantification, and verification
A variety of methods can be used to isolate exosomes. However, there are trade-offs
associated with each method. Table 1-2 summarizes the applications of common EV isolation
methods, indicating advantages and disadvantages of methods for different applications. A
commercial kit makes sense technically for applications where there is a high sample number,
and low volume for each sample.

Table 1-2. Summary of the applications of different exosome isolation techniques.
Method

Principle

Ultracentrifugation
(UC)

-Centrifuge at
increasing
speeds,
eliminating
large cells and
cell debris;
final pellet is
exosomes

Commercial Kits

-Proprietary
polymer that
precipitates
exosomes and
microvesicles
between 30 and
200 nm

Best Used
When
-Larger
volumes (mL)
of biofluid are
available
-Optimal speed
for purity and
yield of
specific
biofluid can be
tested or is
known

-When smaller
amounts of
biofluid are
available
-Specialized
equipment
(UC) is not
available and
there are many
samples from
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Challenges

Citations

-May not be
capable of
differentiating
exosomes from
contaminants
(larger vesicles,
protein and lipid
aggregates).

(SBI, 2018a; T
Skotland et al., 2017;
Thery, Clayton,
Amigorena, &
Raposo, 2006)

-Time consuming
-Difficult to
isolate exosomes
from large
numbers of
samples due to
space constraints
-Multiple
(SBI, 2018a, 2018c)
commercial kit
options
available
-No commercial
kits are
specifically
optimized for
human milk

which EVs will
be isolated
Immunomagnetic

-Magnetic
beads are
coated with
antibodies
against
common
exosomal
markers (CD9
and CD81)

-Highly pure
exosomes are
needed for
downstream
application

-If different
exosome
markers are less
prevalent in a
particular
biofluid, beads
may isolate
fewer
exosomes .

(Pedersen et al.,
2015)

The optimal method of EV isolation may vary depending on the specimen from which
the EVs are isolated. It is therefore important to consider the methods utilized for EV isolation
when interpreting the results of a study. To isolate EVs using differential UC, initial steps
eliminate large dead cells and cell debris by centrifuging at increasing speeds, discarding the
pellet and keeping the supernatant. The final pellet, which appears after centrifuging at 100,000 x
g, contains the exosomes, and is washed in phosphate buffered saline (PBS) and centrifuged one
more time to eliminate contaminating proteins (Thery et al., 2006). Although UC is the most
commonly used EV isolation method (Sáenz-Cuesta et al., 2015; Xin Wang, 2017; Yamada,
Inoshima, Matsuda, & Ishiguro, 2012), it can result in the co-isolation of exosomes, lipoparticles,
and lipid droplets, which alters the lipid composition of EVs as opposed to isolating exosomes
with a typical membrane bilayer (T Skotland et al., 2017). Therefore, if the downstream
application of exosome isolation involves lipid analysis, another method of isolation, such as a
commercial kit should be used instead.
UC has been considered the gold-standard for exosome isolation due to its perceived ease
of use and affordability (Li, Kaslan, Lee, Yao, & Gao, 2017). However, UC is time-consuming,
requires large volumes of biofluid and specialized equipment, and EVs isolated by UC may also

19

be contaminated by proteins (Caradec et al., 2014). The isolation of EVs using UC was
compared, and it was discovered that centrifuging at different speeds impacts the purity and yield
of the EVs that are isolated, since undesirable contaminants such as protein aggregates may
sediment similarly to EVs (Jeppesen et al., 2014). It was found that the optimal speed for purity
and yield differed between two cell lines. Therefore, when a standard UC protocol is utilized to
isolate EVs from a variety of biofluids, it may not be optimized to collect EVs with the greatest
purity and yield from human milk.
Other methods of EV isolation include precipitation-based methods and
immunoprecipitation. Combination methods, such as UC followed by use of a commercial kit
can also be performed. One precipitation method works by using a proprietary polymer reagent
that precipitates EVs between 30 and 200 nm. According to the manufacturer, the kit eliminates
the trade-offs of yield, purity, and speed, and it can be used with as little as 250 μL of specific
biofluids (SBI, 2018c). However, the commercial kits available have not been authenticated for
use of human milk; ExoQuick® is recommended for plasma, serum, and ascites fluid, while
ExoQuick® TC is recommended for isolating EVs from tissue culture (SBI, 2018c).
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a. UC

b. Commercial Kit
Sample collection

Sample collection

Defat milk (centrifuge 2000 x g for
10 min)

Defat milk
(centrifuge 2000 x g for 10 min)
then 3,000 x g for 15 min

Centrifuge 10,000 x g for 30 min
Keep supernatant: pellet = cell

Ultracentrifuge 100,000 x g for 70 min
Pellet= exosomes + contaminating
proteins

Centrifuge supernatant at 12,000
x g for 30 min and discard
debris; filter
Add ExoQuick TC ™ and
incubate overnight at 4 oC

Wash in 1 X PBS and ultracentrifuge
100,000 x g for 70 min
Centrifuge at 5,000 x g for
30 min, and re-suspend in
1X PBS
If desired, purify further
with ExoQuick TC ™

Pellet = exosomes

Figure 1-3. Comparison of UC with a commercial kit for isolation of EVs in human milk. UC adapted
from (Thery et al., 2006) and ExoQuick TC ™(Xin Wang, 2017).
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When isolating EVs, the downstream application and need for intact structure and high
yield must be considered. Using ExoQuick® precipitation, UC with ExoQuick® precipitation,
and UC with density gradient centrifugation, and a protocol for isolating EVs in human milk
(Admyre et al., 2007) with bovine milk, it was found that the human milk isolation protocol
failed to isolate EVs from the bovine milk using the ExoQuick®, as they were unable to suspend
the final EV pellet in PBS for storage due to interference of precipitating proteins (Yamada et al.,
2012). The method was unsuccessful, because the de-fatted bovine milk could not be filtered,
perhaps due to the greater protein content of bovine milk, which clogged the filter. Therefore
subsequent isolation steps could not be performed. UC with ExoQuick® and precipitation
resulted in the highest yield, while density gradient centrifugation resulted in higher quality EV
isolation, with more intact morphological structures, as visualized by electron microscopy. Given
the advantages and disadvantages of each method, the downstream application should be
considered when choosing a method. For example, to analyze total fatty acid content in human
milk, yield is more important than obtaining intact vesicles.
The increased recovery associated with UC and ExoQuickTM precipitation relative to EVs
isolated with UC and density gradient centrifugation may be useful to analyze mRNA kinetics or
exosomal proteins (Yamada et al. 2012). Conversely, the higher purity isolations from UC with
density gradient centrifugation relative to UC and ExoQuickTM precipitation may be more
appropriate for analysis of exosomal proteins. The Yamada et al. (2012) study highlights the
importance of selecting an EV isolation technique based on careful consideration of the type of
specimen from which EVs are being isolated, as well as the downstream application and targeted
use.
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EV verification and quantification methods
After isolating EVs, methods used for verification include immunoblot and electron
microscopy. Immunoblot has been used to confirm EV isolation by detecting the presence of EV
markers such as CD133 and CD63 (J. Kim, Tan, & Lubman, 2015; Sáenz-Cuesta et al., 2015;
Yamada et al., 2012) and the absence of cellular contamination (SBI, 2018a). Using electron
microscopy, EV isolation can be confirmed by observing the characteristic size and shape of the
vesicles (Lobb et al., 2015; Samuel et al., 2017; Sáenz-Cuesta et al., 2015).
Nanoparticle Tracking Analysis (NTA) is used to measure particle size and concentration
and confirm the isolation of EVs (Hock et al., 2017). EV quantification is also performed using
the Bicinchoninic Acid (BCA) protein quantification assay (Thermo Scientific, IL, USA). This
method makes the assumption that protein concentration correlates positively with the
concentration of EVs. The amount of EV protein positively correlates to a greater volume of
biofluid (J. Kim et al., 2015), which supports this assumption. However, this assumption is a
limitation because the relative abundance of EVs between different types of specimen or
between isolation methods cannot be inferred.
Measuring protein concentration in EVs is not always an accurate method of EV
quantification although it has been frequently used. EVs isolated with UC were shown to have a
high albumin content compared to EVs isolated with a precipitation method, impairing the
utilization of protein quantification as a way to accurately quantify EVs (Caradec et al., 2014). EV
protein content quantified with BCA correlated with serum volume in EVs isolated with UC and
a precipitation method (Caradec et al., 2014). However, when NTA was used to quantify
nanoparticles, there was no correlation between the particle number isolated by UC and the original
volume of serum. This suggests that albumin concentration confounded the protein concentration
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measurements. Only comparing the protein contents of EVs isolated with the same technique can
help eliminate the issue of misleading protein quantification results Additionally, EV confirmation
and quantification methods may be more suited to a particular biofluid; for example, it was found
that detection of CD133 markers for Western blot was better with EVs from urine than from blood
(Sáenz-Cuesta et al., 2015).
Functions of milk EVs
EV isolation techniques for human milk need to account for components of the milk
matrix, such as proteins, which could influence the success of an isolation technique.
Additionally, if comparing EVs isolated from milk separately, the timing of obtaining the milk
post-partum should also be considered. Human milk EVs from early and mature human milk
were compared, investigating the influence of lifestyle and allergic sensitization on the profile of
the EVs (Torregrosa Paredes et al., 2014). There were higher levels of HLA-DR antibodies and a
lower concentration of EV protein and a lower number of vesicles in early milk (days 3-8
postpartum) than in mature milk (two months postpartum). These differences in EV composition
and quantity throughout lactation should be considered according to the downstream analysis.
It was also found that there were over 4980 more proteins implicated in immune response
and growth in EVs from bovine colostrum that were not present in mature milk. They were
significantly enriched (p < 0.05) with Rab proteins known for their role in vesicle docking and
fusion as well as with proteins associated with the innate immune response (Samuel et al., 2017).
Further research on these findings may be important to determine if the same differences in
proteins occur in human colostrum and mature milk. Commercially, this knowledge is an
important consideration so manufacturers of infant formula can make consistent products.
Likewise, it was concluded that processing of milk by dairies significantly results in loss of
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miRNAs; pasteurization and homogenization of whole milk decreased miR-200c concentration
63 ± 28% (Howard et al., 2015). Loss of miRNA during homogenization was attributed to lysis
or disruption of EV membranes caused by the shear force applied during homogenization
(Howard et al., 2015). MiRNA loss is problematic, as EVs are involved in cell-to-cell
communication with their cargo, which can include miRNA (Munagala et al., 2016).

In addition to regulation of immune response and inflammation, EVs in milk promote
epithelial growth in the intestine, perhaps because the phospholipid membrane allows the
contents of EVs to reach the intestinal lumen of neonates (Hock et al., 2017a). Necrotizing
enterocolitis (NEC) is the most common gastrointestinal emergency in newborns, and
consumption of human milk has been associated with decreased risk of NEC. The impact of milk
derived EVs on intestinal epithelial cell viability was therefore investigated. Utilizing
Exoquick™ reagent, EVs were isolated from rat milk and a rat small intestine epithelial cell line
(IEC-18) was treated with 0.5-μg/μl EVs, EV-free milk, or an EV-free control solution, finding
that the cells treated with EVs significantly increased IEC viability measured using a
colorimetric assay compared to EV free milk and the control (p < 0.05) (Hock et al., 2017a).
Challenges in the study of human milk EVs
Human milk is frequently refrigerated at 4 °C or frozen at -20 for feeding infants, and at
-80 °C for research purposes and milk banking. Studying human milk samples that were
processed immediately after they were obtained and samples stored for two hours at 4 °C, -20
and -80 °C temperatures, it was discovered that the number of viable cells collected immediately
was donor dependent (Zonneveld et al., 2014). It was found that cell death and subsequent
formation of cell debris impacted the total pool of milk EVs. This could be problematic because
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contamination of the native milk EV with storage-induced EVs can occur if storage induced
stress or cell death induces the formation of new EVs. The disintegration of dead cells can result
in the formation of membrane-enclosed vesicles (Zonneveld et al., 2014). Human milk was
spiked with cells of murine origin to track the formation of storage induced EVs. EVs were
either isolated from the milk right away or stored at -80 °C. A ten to one hundred fold increase in
the murine CD9 and up to a 2,000% increase in murine MHC Class II EV markers stored at 80 °C was observed compared to the immediately processed samples. This suggests the presence
of a newly formed pool of vesicles released by cells during storage that contaminated the pool of
EV naturally occurring in milk (Zonneveld et al., 2014).
Although the Zonneveld et al. (2014) study raises important considerations for
researchers, it is not feasible to eliminate these concerns when researching human milk, as the
only way to do so would be to isolate and study EVs immediately after a mother produced milk.
Some commercial EV isolation kits require an overnight incubation step at 4 oC, and it was
found that the viable cells were decreased after only two hours (Zonneveld et al., 2014). Because
it is not feasible to complete all the necessary analyses and avoid storage of human milk,
consistency is crucial, meaning any aliquots of human milk that are compared should have
undergone identical freeze-thaw processes.
In summary, EVs in human milk may have important functions like mediation of
inflammatory, immune, and epithelial responses. Since lipids and lipid metabolizing enzymes
take part in EV release and formation, fatty acid content may dictate the function of EVs.
However, in order to even carry out structure and function research, a consistent EV isolation
technique suited for the specimen being studied and downstream application is needed. Although
use of a commercial isolation kit to isolate EVs from human milk is a viable option, this method
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has not yet been validated for human milk. Therefore, before structure and function of EVs can
be explored to benefit manufacturers of commercial infant formula products and breastfeeding
mothers, it is crucial that this isolation method is validated for future use.
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2. Rationale and significance
Although human milk is the recommended source of nutrition for most infants, there are
a variety of reasons a parent may need to feed with commercial infant formula to supplement or
replace human milk. Thus, understanding if and how bioactive components of human milk
provide optimal nutrition for infants represents a public health interest that is particularly
relevant to parents and commercial manufacturers of infant formula seeking to replicate the
unique benefits of human milk in products. The present study will address this public health
issue by building upon the established knowledge that fatty acid deficiency has been linked to
deleterious health outcomes, and that the development of a suitable isolation technique for EVs
in human milk has hindered advances in research regarding structural and functional
applications.
It was hypothesized that bioactive components in human milk are related to health
outcomes. The hypothesis was tested through the following objectives:
(1): Determine whether fatty acid composition of milk relates to infant developmental
outcomes reported by the BSID-III.
(2): Develop a feasible method of EV isolation from human milk that satisfies the
International Society of Extracellular Vesicles (ISEV) criteria.
This project has widespread clinical and public health implications, as it could impact
maternal nutrition guidelines in the perinatal period. The proposed research will also contribute
to the product development sector. It is widely accepted that commercial infant formula is
inferior to human milk with respect to several health outcomes. Therefore, if fatty acids in
human milk are correlated to superior developmental outcomes corroborated by standard tests,
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the results of the proposed study can help product developers ameliorate the nutritional quality of
their infant formula. Furthermore, this project will improve knowledge on EV isolation in human
milk, which has not been studied as extensively as EV isolation in other biofluids such as blood
and urine. If the results of the proposed study indicate that the essential fatty acid composition of
EVs in human milk and the fatty acid composition of human milk are associated with favorable
infant health outcomes recorded by standardized health tests, this could pave the way for
maternal dietary recommendations that would favorably manipulate the fatty acid composition of
human milk and EVs in milk.
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3. The relation between the fatty acid composition of human milk and
BSID-III developmental outcomes
Introduction
Human milk is the recommended source of infant nutrition for the first six months of life
(CDC, 2018). The consumption of human milk compared to infant formula has been correlated
with numerous short and long-term benefits, including immune system development, reduced
risk of gastrointestinal and respiratory diseases, superior cognitive development, and reduced
risk of chronic diseases such as diabetes, obesity, and hypertension (Vergilio Visentainer et al.,
2018). Specific benefits of human milk, such as cognitive benefits, have been linked to long
chain fatty acids such as DHA and ARA, which make up about 20% of the brain’s fatty acid
content and are involved in neurodevelopment (Pang et al., 2020). The omega-3 and omega-6
PUFAs are important for human health, growth, and development. Infants consuming colostrum
higher in linoleic acid and lower in DHA exhibited lower IQ scores at five to six years of age
(Bernard et al., 2017). Omega-3 PUFAs are derived from alpha linolenic acid (ALA, 18:3n-3),
while omega-6 PUFAs are derived from linoleic acid (LA, 18:2n-6). Because the precursor
molecules ALA and LA cannot be endogenously synthesized by humans, they are considered
essential. Longer chain fatty acids are synthesized very slowly from the precursor molecules.
Less than 0.1% of LA is converted into ARA (Heaton, Meldrum, Foster, Prescott, & Simmer,
2013). For this reason, consuming pre-converted long chain PUFAs through diet can be a more
efficient way to obtain health benefits.
The Bayley Scales of Infant and Toddler Development – Third Edition (BSID-III) is a
developmental assessment that can be administered to children between one and 42 months of
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age. It is comprised of the Cognitive, Language, Motor, Social-Emotional, and Adaptive
Behavior Scales. Based on the composite scores in the Cognitive, Language, and Motor Scales,
the assessment identifies signs of developmental delay (Bayley, 2006). The Language Scale
assesses receptive and expressive language, and the Motor Scale examines both Fine and Gross
Motor skills (Bayley, 2006).
Previous work has associated higher Mental Development Index scores, a BSID-III
predecessor to the Cognitive Composite, with longer-term consumption of human milk
(Angelsen et al., 2001). Is has also been found that infants whose mothers supplemented with
DHA while breastfeeding exhibited a higher Bayley-II Psychomotor Index (predecessor to
Bayley-III Motor Composite) at 30 months of age (Jensen et al., 2005). Findings from these
studies indicate the association between the consumption of human milk and cognitive and motor
benefits during infancy and childhood. These associations also highlight the need for research to
discover which components in human milk are responsible for these benefits.
Although human milk has been associated with a multitude of acute and long-term benefits,
many of the correlations between human milk and superior cognitive functioning may be
confounded by other factors associated with breastfeeding, such as maternal socioeconomic
status and IQ (Walfisch, Sermer, Cressman, & Koren, 2013) The practice of consuming milk
directly from the breast versus pumped milk may also moderate these benefits. Due to the gap in
knowledge that has resulted from challenges in objectively studying human milk, there is a need
to relate the fatty acid constituents of human milk to infant health and developmental outcomes
using a consistent evaluation such as the BSID-III. It is also necessary to consider proportions of
fatty acids within the milk matrix, as the benefits conferred by single fatty acids may depend on
the presence or absence of other fatty acids. Infant movement quality, for example, which can be
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used to assess neurological development in young infants, was found to be sensitive to the
maternal dietary balance of DHA and ARA. When lactating mothers supplemented with just
DHA, 61% of the infants exhibited mildly abnormal general movements. Only 31% of infants in
the control group (meaning the mother was not supplementing with DHA or ARA) and 34% of
infants whose mothers were supplementing with both DHA and ARA exhibited mildly abnormal
general movements. (van Goor et al., 2010). In the United States, infant formula generally
contains ARA to DHA in a 2:1 ratio, since human milk typically contains greater concentration
of ARA than DHA (Lien et al., 2018). However, more research is needed to determine if the
proportions of these and other fatty acids are optimal for infant health and development.
The objective of the present study was to determine whether the relative amounts of
unsaturated fatty acids in human milk correlated with the Cognitive, Motor, and Language
Composite outcomes reported by the BSID-III. It was hypothesized that there would be a
correlation between greater concentrations of omega-3 EFAs in milk and positive developmental
outcomes reported by the BSID-III. Elucidating the importance of specific fatty acids and fatty
acid ratios in human milk represents a public health interest. Knowledge of the optimal
composition of human milk may facilitate dietary recommendations for breastfeeding mothers
and aid in the manufacture of more nutritious infant formula products.

Methods
Acquisition of human milk and developmental data
The studies involving human participants were reviewed and approved by Chapman
University IRB. The patients/participants provided their written informed consent to participate
in this study (Chapman University REB approval number 1314H044).
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Mothers were recruited by asking eligible women receiving care at University of
California, Irvine clinics in Orange County, California (USA). Inclusion criteria for participating
in the study included: English-speaking, absence of alcohol or drug use during pregnancy,
absence of endocrine, hepatic, or renal disorders, over 18 years of age, and a singleton
pregnancy. Women with a disorder related to uterine or cervical function were excluded. Milk
samples were obtained between 2015 and 2017, and provided between ~9:00 a.m. and 4:30 p.m.
The samples were stored at -80 oC upon collection. The data collected included the Cognitive,
Language, and Motor Scales of the BSID-III. Cognitive, Language, and Motor Composite scores
were obtained at six (n= 60, 61, and 61) and 12 months of age (n= 61, 61, and 61) respectively.
Data on the proportion of human milk feeding was obtained by interview. Data specifying
socioeconomic status, sex of the infant, maternal age and education level, parity, ethnicity, and
cohabitation with the baby’s father was also obtained by interview.
Fatty acid analysis of human milk
Fatty acid analysis of human milk aliquots (n=70) was performed at University of
California, San Diego Lipidomics Core (San Diego, CA, USA). Fatty acids were extracted from
0.5 µL human milk samples with butanol-methanol extraction (BUME). After solvent removal,
samples were saponified by adding 250 µL MeOH and 250 µL 1N KOH, incubating for 60 min
at 37 °C, and neutralizing the pH. Internal standards were added, and fatty acids were extracted
with isooctane. Upon removal of the solvent, fatty acids were derivatized by adding 25 µL 1%
PFBB and 25 µL 1% DIPEA. Samples were incubated at room temperature for 20 min, solvent
was removed, 50 µL iso-octane was added, and samples were transferred to MS vial with insert.
Total esterified and non-esterified fatty acids were quantified using GC-MS (Agilent 5975
GC/Mass Spectrometer, Mass Hunter, Multiquant software) using an injection volume of 1 µL.
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The present study reports on 22:6n-3 (DHA), 20:5n-3 (EPA), 20:4n-6 (ARA), 18:3n-3 (ALA),
18:2n-6 (LA), and 18:1n-9 (OA). The absolute fatty acid concentrations were converted to
relative percentages for subsequent analysis.
Statistical Analysis
Statistical analysis was performed using IBM SPSS® Version 25. Descriptive statistics
were calculated for sample population characteristics, BSID-III outcomes, and relative
concentrations of fatty acids in milk. A simple linear regression analysis was used initially to
model the relation between the relative percentage of the selected fatty acids and the Bayley
Cognitive, Motor, and Language Composite scores at six and 12 months of age before
incorporating covariates and modifiers into the regression model. Maternal age, self-reported
years of education, ethnicity (Latina, non-Latina), infant sex, income to needs ratio (INR) and
cohabitation with the baby’s father were considered as covariates by correlating with predictor
and response variables. Maternal age, education, ethnicity, and INR covariates were chosen to be
incorporated into the regression model.
The percentage of infant diet comprised of human milk at six months was analyzed as a
modifier between the relative proportions of fatty acid and the Bayley outcomes. Modifier values
were incorporated into the regression model, and the p-value of the interaction term between
modifier and predictor was assessed to determine if proportion of milk consumption in diet
modified the relation between fatty acids and BSID-III outcomes. For each regression model
incorporating the modifier, all interaction terms were created with mean-centered variables. A
significance level of α = 0.05 was used throughout the study. The following sample size
calculation was performed to detect a 16% (clinically significant) difference in any Bayley
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subscale score at 80% power in one-tail testing at a 5% level of significance using previously
reported mean and standard deviation (Badr, 2009).

n ≈ [(2*(zpower + z1-a)) ÷ ((μ1 – μ2)/δ)]2
n ≈ [(2*(0.8416 + 1.96)) ÷ (16/15)]2
n ≈ 35 (per timepoint)
Equation 3-1. Sample size calculation for determination of clinically significant differences in
Bayley subscale score means.
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Results
Table 3-1. Maternal and demographic information and categorical level of education for the 70
mother-child pairs in the present study. INR is reported as percent above or below the poverty
line.
Infant and Maternal
Demographic

Values

Infant characteristics

Male, n
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Highest Level
of Maternal
Education
Attained
(n=70 )
Primary,
elementary, or
middle school

Number of
Participants
(%)

High school or

11 (15.7%)

3 (4.3%)

GED
equivalent
Female, n
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Technical or

7 (10%)

vocational
school
Birth order (%)

Some college,

9 (12.9%)

but no degree
First born

36 (51.4%)

Second born

23 (32.9%)

Third born

8 (11.4 %)

Fourth born

2 (2.9%)

Sixth born
Maternal
characteristics

1 (1.4%)
Associate’s
degree

Latina/Chicana/Hispanic, 30

Bachelor’s

n

degree

Cohabiting with baby’s
father, n, yes

3 (4.3%)

70, 63

Other graduate
degree

36

18 (25.7%)

16 (22.9%)

(Master’s,
Income to needs ratio (n,
mean ± SD, median)
Average years of
education, (n, mean ±
SD)

Doctorate)
68, 474.72 ±

Certificate

3 (4.3%)

489.35, 364
68, 15.67 ±
3.28

Table 3-2. Descriptive statistics for the Bayley Cognitive, Motor, and Language Composite
scores at six and 12 months of age.
Scale
Cognitive
Composite
Cognitive
Composite
Motor
Composite
Motor
Composite
Language
Composite
Language
Composite

Time
Mean
(month) N
6
60
102.83

Minimum Maximum SD
75

120

10.27

12

61

105.66

85

135

11.20

6

61

93.61

65

115

10.69

12

61

96.40

73

121

10.00

6

61

97.62

77

115

9.02

12

61

99.66

77

132

10.00

Table 3-3. Descriptive statistics for the select fatty acid composition of human milk (n=70)
reported as relative percentages.
Fatty Acid
DHA
EPA
ARA
ALA
LA
OA
ARA/LA
DHA+EPA
(DHA+EPA)/ALA

Mean
Minimum Maximum SD
0.729
0.2
2
0.423
0.089
0
0.3
0.075
0.883
0.5
2
0.279
1.414
0.5
3.7
0.517
14.569
6.9
28.4
3.257
35.830
25.1
47.9
4.185
0.063
0.024
0.17
0.025
0.817
0.2
2.3
0.482
0.676
0.125
3
0.542
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Table 3-4. Linear regression analysis for fatty acids and BSID-III scores. Simple linear
regression tables comparing fatty acids and (A) Bayley Cognitive Composite, (B) Motor
Composite, and (C) Language Composite scores at six and 12 months of age. Statistically
significant correlations (p <0.05) are denoted with an asterisk (*). B represents the
unstandardized coefficient while β represents the standardized coefficient.

A)

6 Months

DHA
EPA
ARA
ALA
LA
OA
ARA/LA
DHA+EPA
(DHA+EPA)/ALA

R2

B

β

p

R2

B

β

p

0.004
0.030
0.005
-0.007
-0.014
0.031
-0.015
0.009
0.010

3.498
30.769
-5.246
2.246
0.198
-0.552
25.959
3.443
3.184

0.144
0.215
-0.147
0.099
0.054
-0.218
0.051
0.160
0.163

0.274
0.099
0.263
0.453
0.682
0.094
0.701
0.223
0.214

-0.006
-0.016
0.057
-0.016
-0.015
-0.017
0.036
-0.008
0.005

2.913
4.926
-10.498
-0.606
-0.179
0.054
-101.629
2.371
3.223

0.103
0.032
-0.269
-0.025
-0.045
0.020
-0.228
0.096
0.146

0.428
0.809
0.036*
0.850
0.731
0.880
0.077
0.463
0.260

B)
DHA
EPA
ARA
ALA
LA
OA
ARA/LA
DHA+EPA
(DHA+EPA)/
ALA

12 Months

6 Months

12 Months

R2

B

β

p

R2

B

β

p

-0.017
-0.017
0.044
-0.015
-0.012
-0.016
-0.015
-0.017
-0.001

-0.162
-1.152
-11.23
-1.395
-0.330
0.121
29.135
-0.154
3.145

-0.005
-0.006
-0.246
-0.048
-0.070
0.037
0.044
-0.006
0.126

0.968
0.961
0.056
0.712
0.590
0.776
0.734
0.966
0.333

-0.006
-0.003
0.018
0
-0.007
-0.014
-0.012
-0.011
-0.005

-1.586
-16.388
-6.455
-2.798
-0.345
-0.121
-27.34
-1.636
2.134

-0.063
-0.118
-0.185
-0.128
-0.097
-0.050
-0.069
-0.074
0.109

0.629
0.366
0.153
0.327
0.457
0.703
0.598
0.571
0.404
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C)

6 Months

DHA
EPA
ARA
ALA
LA
OA
ARA/LA
DHA+EPA
(DHA+EPA)/
ALA

12 Months

R2

B

β

p

R2

B

β

p

0.002
0.041
0.034
0.021
-0.007
-0.008
-0.011
0.008
-0.015

3.456
35.359
-8.392
4.601
0.387
0.253
-39.464
3.517
0.858

0.136
0.238
-0.224
0.194
0.100
0.095
-0.073
0.156
0.042

0.297
0.065
0.083
0.135
0.441
0.466
0.574
0.229
0.748

0.01
-0.016
0.050
-0.015
-0.015
-0.008
-0.004
0.002
-0.009

-4.063
-16.388
-8.940
-2.798
0.172
0.235
44.851
-3.034
-1.786

-0.161
-0.118
-0.256
-0.128
0.048
0.096
0.113
-0.137
-0.091

0.214
0.366
0.046*
0.327
0.712
0.460
0.387
0.292
0.486

Table 3-5. Regression analysis of ARA and Bayley Cognitive Composite and Language
Composite scores at 12 months of age after adjusting for the following covariates: Self-reported
years of maternal education, maternal age, INR, ethnicity

ARA

Cognitive 12 Months
B
β

p

-10.282

0.048

-0.266

Language 12 Months
B
β
-8.145

-0.235

p
0.083

Table 3-6. Linear regression model of ARA in relation to Bayley Cognitive Composite scores at
12 months of age after incorporating the following modifier: Percentage of infant diet comprised
of human milk at six months.

(ARA)*(% Milk)
ARA
% Milk

B
-0.073
-9.556
0.014

β
-0.088
-0.258
0.054

p
0.571
0.11
0.697

The participants in the present study consisted of 70 mothers recruited in Orange County,
CA (USA). Demographic information was obtained (Table 3-1), and descriptive statistics were
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calculated for BSID-III scores of the infants (Table 3-2) and for the fatty acid composition of
human milk from participants (Table 3-3). At six months, the relation between the individual
fatty acids, fatty acid ratios, and BSID-III Cognitive Motor, and Language Composite scores was
not statistically significant (Table 3-4A-C). However, the relative percentage of ARA was
significantly correlated (p<0.05) with Bayley Cognitive Composite scores at 12 months of age
(Table 3-4A). After including the following covariates in the regression model, this relation
remained statistically significant: maternal age, education, ethnicity, and INR (Table 3-5).
Prior to accounting for covariates, ARA was significantly correlated to Bayley Language
Composite scores at 12 months of age (Table 3-4C). However, after including covariates in the
regression model, this relation became a non-significant trend (p>0.05<0.10) (Table 3-4C). The
following non-significant trends were also observed in the simple linear regression models: the
relation between ARA and Bayley Cognitive Composite scores at six months, OA and Bayley
Cognitive Composite scores at six months, ARA/LA and Bayley Cognitive Composite scores at
12 months, EPA and Bayley Language Composite scores at six months, and ARA and Bayley
Language Composite scores at six months.
Potential modifiers based on the exclusivity of human milk consumption were also
considered (Table 3-6). At six months of age, 63 participants out of 70 reported the percentage of
infant diet that was comprised of their human milk (data not shown). It was found, however, that
the percent of diet from human milk at six months did not moderate the association between
ARA and Bayley Cognitive Composite scores (Table 3-6) (all p values > 0.05).
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Discussion
The relative amount of ALA, ARA, and EPA in milk of participants in the present study
(Table 3-3) is similar to values reported in literature (Barreiro et al., 2018). An analysis of the
fatty acids in milk from women in Northwest Spain at was similar to milk in the rest of Europe
and the world at the same or similar points of lactation (Barreiro et al., 2018). However,
several fatty acids quantified for the present study at two weeks of lactation differed from the
values from one month of lactation reported by (Barreiro et al., 2018). In the present study,
milk from participants had a greater mean concentration of DHA (0.73%) than participants in
previously reported studies (0.36%) (Barreiro et al., 2018). Additionally, milk from
participants in the present study contained a mean concentration of ARA almost double that of
a previously reported study (0.883% and 0.49% respectively) (Barreiro et al., 2018).
Table 3-1. Average fatty acid content of human milk at one month postpartum in mothers from
Northwestern Spain (Barreiro et al., 2018) compared to the fatty acid content of human milk in
the present study.
Fatty Acid
DHA

Average Relative
Percentage (Barreiro et
al., 2018) (n=157)
0.36 ± 0.17

Average Relative
Percentage in the
Present Study (n=70)
0.729 ± 0.423

EPA

0.11 ± 0.05

0.089 ± 0.075

ARA

0.49 ± 0.11

0.883 ± 0.279

ALA

0.48 ± 0.12

1.414 ± 0.517

LA

14.12 ± 3.16

14.569 ± 3.257

OA

34.3 ± 2.61

35.83± 4.185

Human milk from two weeks and one month postpartum are comparable for research
purposes, as after two weeks, milk is considered generally mature (Ballard & Morrow, 2013).
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Thirty of the 70 participants in the study were Hispanic/Latina (Table 3-1A). However, it is
unlikely that elevated DHA composition in the milk obtained from participants of the present
study is related to ethnicity. In fact, the fatty acid concentration of DHA in the milk of women in
other areas of the world, such as Latin America, was found to be similar to fatty acid profiles
from Europe (Barreiro et al., 2018). Thus, the increased concentration of DHA in the milk of
women in the present study is likely diet-related. However, maternal dietary records were not
obtained to confirm this.
ARA was inversely related to Bayley Cognitive Composite scores at 12, but not six months
of age (Table 3-4;Table 3-6). The importance of this observation extends beyond infancy, since
Bayley Cognitive Composite scores in infancy are an indicator of cognitive development in
childhood (Berk, 2013). In the present study, the composition of human milk at two weeks
postpartum predicted BSID-III Cognitive development at 12 months. The lack of statistically
significant findings at six months of age may be attributed to greater accuracy of the health and
behavioral assessments at 12 months of age, when infants are more emotive and expressive than
at six months of age. In fact, one critique of the BSID-III is that the reliability is lacking for
younger children (aged zero to six months). However, reliability is an inherent challenge in any
instrument intended for use in populations with high developmental variation, such as young,
rapidly developing infants.
In the present study, DHA was not significantly correlated with developmental outcomes at
six or 12 months of age. It was previously found that infants whose mothers supplemented with
DHA during breastfeeding exhibited a higher Bayley-II Psychomotor Index (predecessor to
BSID-III Motor Composite) at 30 months of age, but not at any 12 months of age (Jensen et al.,
2005). However, the advantage of a higher Psychomotor Index was unclear, since the mean of all
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groups was above the expected mean. The delayed effect of psychomotor development may have
been observed because DHA early in life is necessary for developmental domains that are
manifested later in life, or because DHA confers psychomotor benefits that are not detected due
to the lack of sensitive tests early in life (Jensen et al., 2005). Therefore, it is possible that DHA
or another fatty acid in the present study may have been significantly correlated to Bayley Motor
scores if results past 12 months were recorded.
The amount of variation in BSID-III scores explained by fatty acids and fatty acid ratios in
statistically significant regression models is smaller than R2 = 0.1, and can thus be classified as
“small,” (Murphy & Myors, 2004) (Table 3-4;Table 3-6). However, a single fatty acid or fatty
acid ratio explaining even 5-10% of the variation in complex development outcomes influenced
by other factors such as genetics could have major public health implications, including
personalized nutritional recommendations for lactating mothers, and the development of milk
fortifiers and infant formulas. Although mothers cannot change genetic factors that may
influence the composition of their milk, nutrition is a more accessible and easily-implemented
strategy to optimize the nutritional benefits of human milk consumed by infants.
In the present study, ARA was inversely correlated with Bayley Cognitive Composite
scores at 12 months after covariate analysis. Relative percentages of other essential fatty acids to
which developmental benefits have previously been attributed, such as DHA, did not correlate
with BSID-III outcomes. However, this may be due to the specific population in the present
study. The average relative percentage of DHA reported in the present study was 0.729%
compared to 0.36% reported in a previous study at a similar timepoint (Table 3-3). The majority
of the infants in the present study may therefore have consumed DHA in excess of levels
necessary to confer health and developmental benefits. Hence, variations in the levels of DHA in
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the human milk studied may not have predicted developmental outcomes due to the absence of
samples containing little to no DHA. Future work studying human milk with more of a range of
DHA concentrations and the ratio of DHA/ARA may provide more insight. It should also be
noted that the sample size calculation (Equation 1) does not include the incorporation of
covariates. Given the rigorous incorporation of four covariates in the present study, a larger study
group may yield statistically significant results in Bayley Language Composite scores after
covariate analysis.
The average relative percentage of ARA in the milk of participants in the present study was
roughly twice as high as previously reported (Table 3-7). ARA has been associated with
cognitive development in infants, and is typically added to infant formula in a 2:1 ratio with
DHA in the United States (Lien et al., 2018). In the present study, the ratio of ARA to DHA was
1.1 to 1 (Table 3-3). Interestingly, previous work reported a reduced benefit in some cognitive
measures when infants consumed formula with a higher DHA to ARA ratio (1.5:1) compared to
intermediate doses of DHA (1:1 and 1:1.5 DHA to ARA). This effect was observed at 60 and 72
months using the Peabody Picture Vocabulary Test, 3rd edition and the Full Scale IQ derived
from the Wechsler Preschool and Primary Scale of Intelligence, 3rd edition respectively
(Colombo, Shaddy, Kerling, Gustafson, & Carlson, 2017). Colombo et al. (2017) noted that
previous research of LCPUFA distribution in the brain tissue of baboons displayed a similar
trend. Baboons that were fed the highest dose of DHA:ARA (also a 1.5:1 DHA:ARA ratio) in
formula indicated a reduction in the tissue concentration of ARA in all areas of the brain. By
studying the fatty acid composition of red blood cells in the infants, it was determined that the
DHA composition of red blood cells at 4 and 12 months of age plateaued between infants
consuming the intermediate and high doses of DHA:ARA, indicating saturation at the highest
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dose. Increased concentrations of specific fatty acids in human milk and formula may therefore
lead to lower accretion of other fatty acids in areas of the brain, resulting in the reduction in
cognitive benefits. Additionally, similar to the findings of the brain tissues in baboons, the
concentration of ARA in red blood cells actually decreased in response to the highest dose of
DHA compared to the intermediate doses (Colombo et al., 2017).
It was previously hypothesized that a high ratio of omega-3 to omega-6 fatty acids led to
the inhibition of Δ6-desaturase, impeding the conversion of LA to ARA, making ARA
unavailable for growth (Hadley, Ryan, Forsyth, Gautier, & Salem, 2016). In the present study,
however, the concentration of both DHA and ARA were higher than previously found, so this
may not be a plausible explanation for the inverse correlation between ALA and infant
development. Additionally, due to low conversion rate of LA to ARA, the levels of these fatty
acids in human milk are primarily reflective of the preformed DHA and ARA consumed in diet.
Thus, the mechanistic relation between fatty acids, such as ARA, and developmental outcomes is
exceedingly complex, and should consider relative percentages of specific fatty acids interacting
in the complex milk matrix.
Adequate concentrations of PUFAs in the brain early in life are important, because fatty
acids influence processes such as membrane dynamics and cell signaling. As the infant’s brain
grows, levels of ARA and DHA increase during the last three months of pregnancy and during
the first five years of life. Importantly, dietary intake of fatty acids early in life affects fatty acid
accretion in the brain. In contrast to the cerebral cortex, which is of interest for higher-level brain
functioning, the cerebellum is important for movement and balance. The percentage of DHA in
white matter in the cerebellum has been found to be lower in formula fed infants than in infants
fed human milk. However, no differences in cerebellar white matter content were observed for
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ARA (Lien et al., 2018). EFA are thought to promote development through a variety of
mechanisms. While DHA is understood to control signaling membranes in the brain and nervous
system, ARA is important for brain growth during gestation and early in infancy, where it plays a
role in cell signaling and division. ARA mediates various functions in the brain, including
neuronal firing, signaling, and long-term potentiation. Among other functions, ARA also
maintains membrane order and hippocampal plasticity (Hadley et al., 2016).
Understanding accretion of fatty acid levels in areas of the brain associated with specific
functions may mechanistically implicate the role of specific fatty acids in different development
functions. Moreover, quantifying the proportion of fatty acids necessary for optimal development
may lead to greater understanding of structure-function relationships. This knowledge may also
facilitate application of this knowledge to nutritional recommendations and development of milk
fortifier and infant formula products. The present study represents novel research, because
specific percentages of ARA present in human milk, instead of infant formula, have now been
quantified and correlated to BSID-III Cognitive, Motor, and Language scores. BSID-III
outcomes can be extrapolated more broadly to cognitive, motor, and language ability in infants.
Objectively quantifying and relating fatty acids in human milk to development is necessary to
develop nutritional guidelines for breastfeeding mothers and to inform the development of infant
nutrition products. Quantitative knowledge implicating specific percentages of product to
precursor fatty acids in relation to development is also a segue to future work considering the
FADS gene and maternal and infant genotype.
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Limitations
The present study has several limitations. The gold standard of milk collection involves
sampling all milk expressed over 24 hours (Ballard & Morrow, 2013). This was not the practice
for the present study. In addition to limitations related to the collection of milk aliquots, the
scope of the present study also presents a limitation. Maternal and infant genotyping was not
performed, so genotype could not be incorporated into the regression models as a modifier. It is
well known that there is inter-individual variability in the metabolism of fatty acids. The
FADS-1 and FADS-2 enzymes encoded by the FADS gene modulate the synthesis of ARA and
DHA from LA and ALA respectively. Polymorphisms in the FADS-1 and FADS-2 genes encode
the enzymes that alter the production and thus concentration of LC-PUFAs (Lattka et al., 2009).
In future work, controlling for how efficiently lactating mothers can synthesize LC-PUFAs that
are present in milk and how efficiently infants can synthesize LC-PUFAs from the precursors in
the milk they consume will provide a more objective measure of the developmental outcomes
associated with specific essential fatty acids. An additional limitation of the present study is that
maternal diet and supplementation records were not obtained. For a more comprehensive
analysis, future work could include maternal diet and supplementation records in addition to
infant and maternal genotyping.

Conclusion
In conclusion, the relative percentage of ARA in human milk may influence language and
cognitive ability in infants. There was an inverse relation between ARA and Bayley Cognitive
Composite scores at 12 months of age, and an inverse relation (non-significant trend) between
ARA and Language Composite scores 12 months of age. Exclusivity of human milk feeding at
six months did not modify BSID-III outcomes in the study population. Future work with a larger
sample population may yield additional statistically significant results after accounting for
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covariates. Furthermore, future work accounting for other known modifiers, such as maternal
and infant FADS genotype, may provide a more thorough understanding of the relation between
essential fatty acids and development. The statistically significant correlations and nonsignificant trends observed in present study prompt further consideration of optimal proportions
of fatty acids in human milk and infant formula to inform nutritional recommendations for
breastfeeding mothers and product development initiatives.
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4. Isolation of EVs from Human Milk
Introduction
It is well-known that consumption of human milk is associated with enhanced infant
health outcomes in comparison to consumption of infant formula. However, it is not fully known
which components of human milk may be responsible for supporting optimal health and
development of newborns. Increasing research suggests that EVs from human milk have
physiologic function that may impact acute and chronic health outcomes. Human milk EVs
promote epithelial cell growth in the intestine (Hock et al., 2017a) and were found to protect
intestinal epithelial cells from oxidative stress (C. Martin, Patel, Williams, Arora, & Sims, 2018).
Additionally, human milk EVs have been implicated in the immune modulating function of
human milk, and may play a role in the development of the neonatal immune system (Zonneveld
et al., 2014). These effects may be attributed to the protein, lipid, or microRNA cargo of human
milk EVs (Zonneveld et al., 2014). A reliable method for consistent isolation of EVs from human
milk is needed to determine the functional components of EVs to which enhanced infant health
outcomes can be attributed.
Although UC is the most commonly used method to isolate EVs from biospecimens (T
Skotland et al., 2017), the feasibility of this method for human milk research is limited. As a
precious biofluid for feeding newborns, acquiring the large volume of human milk needed for
EV isolation using UC is not always feasible. Unfortunately, no method of EV isolation has been
authenticated for use with a low volume of human milk (≤2 ml); prior studies have isolated
human milk EVs from a starting volume of 9 mL (Vaswani, Qin Koh, Almughlliq, Peiris, &
Mitchell, 2017). As a result, the limitations in conducting research in this area have created a
knowledge gap. Additionally, authentication of an EV isolation method from low volumes of
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human milk will facilitate research on EVs throughout milk production periods, the course of
lactation, over time-of-day variation, and perhaps most importantly in low volume producers,
which are not adequately studied.
This limitation has several potential negative consequences. First, analysis of only large
volumes may limit research to use of pooled human milk. This measure would result in a greater
understanding of average milk composition but not of interindividual variability. Second,
analyses may be limited solely to time of lactation when higher volumes of milk are produced.
This may then result in a disparate understanding of mature milk relative to early and transitional
milks. Finally, research may be limited to studies of mothers with high volume of milk
expression instead of low volume producers. Therefore, a strong need exists for a method of
isolate EVs from a low volume of human milk.
A novel method for the isolation of EVs requires verification procedures. The
International Society for Extracellular Vesicles (ISEV) released MISEV guidelines in 2018
(Théry, Witwer, & Aikawa, 2018) detailing the minimum criteria for confirming isolation of
EVs. MISEV guidelines recommend that each EV preparation be (i) defined quantitatively by the
source of EVs, (ii) characterized to determine the abundance of EVs by total particle number or
protein/lipid content, (iii) tested for components associated with EV subtypes or EVs generically,
and (iv) tested for the presence of non-vesicular co-isolated components. This paper describes a
precipitation-based method for the isolation of EVs from human milk. The subsequent
characterization of EVs suggest successful isolation in compliance with the MISEV guidelines.
EVs isolated using the present method are therefore appropriate for downstream characterization
and functional analyses to better understand the health and immune-modulating properties of
human milk.
50

Methods
Mature milk (>6 months after initiation of lactation) was pooled and pasteurized from donors to
develop the EV isolation method (Prolacta Bioscience, City of Industry CA). Twelve volunteers
also provided samples of expressed milk between 2 and 4 weeks postpartum which were
immediately frozen at −80°C. Ethics approval was obtained from the Chapman University
Institutional Review Board. The EV isolation method (Figure 4-1) outlined herein is adapted
from the instructions for a commercial precipitation reagent (SBI, 2018b) and a previously
published protocol (X. Wang, 2017).

Thaw human milk
aliquots

Centrifuge at 2,000 x
g, 10 min, remove fat
layer. Ideally, defat
before freezing.

Centrifuge de-fatted
milk at 12,000 x g
for 30 min, discard
debris at bottom of
tube

Centrifuge
ExoQuick™-milk
supernatant mixture
(5000 x g for 30
min). Pellet = EVs.

Add ExoQuick-TC™
reagent (5:1 milk:
ExoQuick TC™) and
incubate overnight at
4 oC

Filter milk through
0.45 μm cellulose
syringe filter

Re-suspend pellet in
PBS

Freeze EVs at -80 oC
or use immediately
(optimal) or within
three days of
isolation

Figure 4-1. Workflow schematic for EV isolation using a precipitation-based isolation method.
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EV Isolation Method
Thawing, Defatting, and Removal of Cell Debris
1. Thaw frozen human milk at 4°C. Once thawed, vortex milk for ~3 s.
2. If milk was not aliquoted into microcentrifuge tubes prior to freezing, aliquot 1.5–2 mL (or
desired volume) human milk into microcentrifuge tubes.
3. Centrifuge at 2,000 × g for 10 min to separate and remove the fat layer with a metal spatula.
Discard the fat layer and transfer milk to a new tube. Removing the fat layer also removes
milk fat globules (Le et al., 2009).
4. Centrifuge the defatted milk at 12,000 × g for 30 min to remove cell debris. Transfer milk
supernatant and/or discard pellet.
5. Filter milk supernatant through a 0.45 μm cellulose syringe filter into a new microcentrifuge
tube to further eliminate cells and cellular debris.
EV Isolation
6. Using a 5:1 ratio of milk supernatant: ExoQuick-TC™ reagent (System Biosciences, Palo
Alto CA), add reagent to the filtered milk and gently invert until mixed.
7. Incubate at 4°C overnight or for at least 12 h.
8. After incubation, centrifuge at 5,000 × g for 30 min (beige pellet will appear at the bottom of
the tube).
9. Discard supernatant, and resuspend EV pellet in 100–600 μL PBS (pH 7.4).
10. Depending on downstream application, use resuspended EVs stored at 4°C within 3 days or
freeze immediately at −80°C.
Scanning Electron Microscopy
Zeiss Gemini Sigma 300 scanning electron microscope (SEM) was used to visualize EVs
isolated from milk expressed at 2 weeks postpartum (n = 1 volunteer). EVs were visualized 1 day
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after they were isolated, resuspended, and stored at 4°C. The original EV resuspension in PBS
(500 μL) was further diluted in PBS (1:1,000). SEM slides were prepared with 2 μL of diluted
EVs. Argon gas sputter coating of EVs with 3 nm gold-palladium alloy was performed to prevent
sample destruction.
Nanoparticle Tracking Analysis
Nanoparticle Tracking Analysis (NTA; Nanosight NS01) was used to determine the
concentration and size of EVs isolated from the pooled milk sample. A sample of EVs originally
resuspended in PBS (500 μL) and frozen at −80°C was thawed on ice and further diluted in PBS
(1:75) prior to injection. Detection threshold was set to four, and three runs each of 30 s in
duration were completed and analyzed using NTA 3.1 software. Total yield (EV particles/mL
milk) was calculated based on dilution factors and a starting volume of 1.5 mL milk.
Dynamic Light Scattering
The diameter of EVs isolated from the pooled milk sample was measured with a Mobius
Dynamic Light Scattering (DLS) instrument (Wyatt Technology) using DLS Firmware Version
1.2.0.0. Laser wavelength was set to 532 nm, and a detector angle of 163.5° was used. DLS
acquisition time was set to 5 s and a number acquisition of three was used to perform three
technical replications on EVs stored at 4°C over the course of 10 days.
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Exocheck Antibody Array
The Exocheck™ Antibody Array (System Biosciences, Palo Alto CA) was used according to the
manufacturer's instructions (SBI, 2018a) to determine the presence or absence of common EV
proteins (CD63, EpCAM, Annexin5, TSG101, Flotilin1, ICAM, ALIX, CD81) in EVs isolated
from milk expressed at 4 weeks postpartum (n = 1 volunteer). Resuspended EVs were thawed on
ice prior to antibody array analysis.
Determination of Total Fatty Acid Concentration
The EVs from which fatty acids were analyzed were isolated using 2 mL aliquots of pooled milk,
and with variations in EV isolation steps. A 5:1 and 10:1 ratio of milk supernatant: ExoQuickTC™ reagent was used with or without (0.45 μm cellulose) filtration or purification using
ExoQuick-TC™ ULTRA purification columns according to the manufacturer's instructions
(System Biosciences, Palo Alto, CA). Prior to fatty acid analysis, EVs were isolated from the
pooled milk sample, resuspended in PBS (500 μL), frozen at −80°C, and thawed on ice. Fatty
acid analysis was performed by Creative Biostructure (Shirley, NY USA).
The total fatty acid concentration of EVs was determined by colorimetric analysis in triplicate
(n = 1 per isolation variation). Standards were prepared with palmitic acid (1 nmol/μL). Samples
were diluted and homogenized. Standard dilution (50 μL) or sample (0.5–25 μL) were added to
each sample well. The final volume was adjusted to 50 μL with assay buffer. An acyl-coenzyme
A synthetase reagent (2 μL) was added to each reaction well, mixed, and incubated (20 min,
37°C). Samples were then incubated (30 min, 37°C) in the dark with reaction mix (2 μL)
containing assay buffer (44 μL), fatty acid probe (2 μL), enzyme mix (2 μL), and enhancer (2
μL). Finally, optical density was measured on a microplate reader at 562 nm.
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Protein Quantification
A Qubit™ 4 Fluorometer was used to measure the protein concentration in human milk EVs
isolated from milk expressed at 2 weeks postpartum (n = 10 volunteers). Resuspended EVs were
thawed on ice prior to protein quantification. The instrument was calibrated with protein
standards according to the manufacturer's instructions (ThermoFisher, 2018). EV samples
originally resuspended in 600 μL PBS were thawed on ice and diluted in PBS (1:20). Lysis
buffer (10 μL) was added and samples were vortexed (Protease Inhibitor Cocktail, RIPA buffer,
Thermo Fisher Scientific, Waltham MA). Protein concentration was measured in duplicate after
incubating (15 min, room temperature) the lysate (1 μL) with working reagent (199 μL). Protein
quantification of EVs was calculated based on dilution factors and a starting volume of 1.5 mL
milk.

Results
SEM (Figure 4-2), NTA (Figure 4-3) DLS (Figure 4-4), and an antibody array (Figure 4-5) were
used to image, quantify, measure the average diameter, and identify protein markers
characteristic of EVs. The image obtained by SEM revealed the size of nanovesicles in the
expected range for EVs, approximately 50–350 nm (Figure 4-2). Results from analysis by NTA
revealed that the isolation method yielded 8.9 × 109 (± 1.1 × 109) particles/mL of human milk.
The mean and mode diameter of EVs were 179.3 and 150.3 nm, respectively (Figure 4-3). No
standard deviation is reported for the mean since a trimodal distribution of EV populations was
observed. Results from DLS (Figure 4-4) showed that the average diameter of EVs 1 day after
isolation was 213.6, and 249.7 nm 10 days after isolation. Error bars for individual days were
excluded because individual standard deviations for technical replicates were <5% of the mean.
Antibody array (Figure 4-5) indicated that the sample was positive for the following known EV
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markers: cluster of differentiation 81 (CD81), ALG-2-interacting Protein X (ALIX), intracellular
adhesion molecule (ICAM), tumor susceptibility gene 101 (TSG101), and Annexin5, and
negative for cluster of differentiation 63 (CD63), epithelial cell adhesion molecule (EpCAM),
and flotilin1.

2 µm

Figure 4-1. Image of EVs obtained by SEM from participant (n = 1), Electron high tension =
5.00 kV, working distance = 20.9 mm, detector = secondary electron, magnification = 8.70 K X,
vacuum mode = high vacuum, height = 9.851 μm.
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Figure 4-3. Diameter and concentration of human milk EVs from pooled human donor milk
measured by NTA. Technical replicates were performed in triplicate (solid line = trial 1; dashed
line = trial 2; dotted line = trial 3) (A) and the average of the three runs was calculated (B). The
above graphs are plotted from the 10th−90th percentile of EV sizes (22.5–312.5 nm) to exclude
particles which do not meet the size criterion for likely EVs.
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Figure 4-2. Average diameter of EVs from pooled human donor milk measured for 10
consecutive days after isolation and storage at 4°C. Error bars were excluded because individual
standard deviations were <5% of the mean. Pooled SD = 33.45.
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Figure 4-3. Antibody array of human milk EVs from participant (n = 1). PC represents the
positive control, and GM130 is a cellular contamination marker. CD 63 = cluster of
differentiation 63, EpCAM = epithelial cell adhesion molecule, TSG101 = tumor susceptibility
gene 101, ICAM = intracellular adhesion molecule, ALIX = ALG-2-interacting Protein X, CD81
= cluster of differentiation 81.
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After verification of isolation, human milk EVs were characterized by quantifying total fatty
acids (Figure 4-6) and protein concentration (Table 4-1). The average total fatty acid
concentration of EVs isolated with the recommended method (5:1, filter, no column purification)
was 36.94 mg/dL. The mean protein concentration of human milk EVs was 5.08 (±0.15) mg/dL.
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Figure 4-4. Antibody array of human milk EVs from participant (n = 1). PC represents the
positive control, and GM130 is a cellular contamination marker. CD 63 = cluster of
differentiation 63, EpCAM = epithelial cell adhesion molecule, TSG101 = tumor susceptibility
gene 101, ICAM = intracellular adhesion molecule, ALIX = ALG-2-interacting Protein X, CD81
= cluster of differentiation 81.
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4.329 nmol FA
x 500 µL PBS = 2,164.5 nmol FA
µL
2,164.5 nmol FA 1443 nmol FA
=
1.5 mL
mL milk

0.000000256 g 1443 nmol 36.94 mg EV FA
x
=
mL
dL human milk
nmol

Equation 4-1. Calculation of average concentration of fatty acids present in human milk EVs.
Total fatty acids were measured.
Table 4-1. Protein concentration of EVs isolated from human milk of 10 different participants
measured in duplicate.
Sample
1
2
3
4
5
6
7
8
9
10
Mean
SD

Protein content (mg/dL milk)
5.20
5.00
5.11
5.02
5.15
5.18
5.24
4.98
5.20
4.75
5.08
0.15

Discussion
The method of EV isolation from human milk described herein meets the MISEV criteria
(Théry et al., 2018) for verifying the presence of EVs. EVs isolated with the proposed method
were (i) quantified in relation to the source of human milk, (ii) characterized to determine the
abundance of EVs by total particle number and lipid & protein content, (iii) tested for the
presence of markers associated with EVs, and (iv) tested for the presence of non-vesicular coisolated components. The method adapted from manufacturer instructions for a precipitation

60

reagent (SBI, 2018b) and previous literature (X. Wang, 2017) was shown to be suitable to
adequately characterize EVs isolated from human milk and for downstream applications.
There is consistency between the average EV diameter measured by SEM, NTA, and
DLS (Figures 4-2, 4-3, and 4-4). Unlike NTA which generates size distribution data, DLS
measures the average particle diameter. Measurement by DLS then may be skewed by low
concentrations of outliers or clustering of particles (Van der Pol et al., 2010). Therefore, the
~15% difference in diameter between SEM, NTA, and DLS measurements could be due to
overestimation of diameter by DLS. The recommended method presented herein yielded 8.9 ×
109 (± 1.1 × 109) EV particles/mL of human milk. Another group isolated human milk EVs and
reported a yield of 8.0 × 1010 particles/ml of milk using a UC based method (Vaswani et al.,
2017). The difference in yield could be attributed to the fact that banked, pasteurized milk was
used in the present method. Additionally, EVs were frozen and thawed prior to quantification
without defatting before initial freezing, which has shown the decreased recovery of EVs
(Zonneveld et al., 2014).
In the MISEV guidelines, it is recommended that operational terminology for
extracellular vesicles based on factors such as size be used. EVs <200 nm in diameter would be
considered “small,” and EVs >200 nm considered medium or large (Théry et al., 2018). Results
from NTA indicated that the greatest concentration of particles is around 153 nm (Figure 4-3),
meaning the EV population in highest abundance would be classified as small. The 10th−90th
percentile of particle size were graphed (Figure 4-3) as particles outside this range were likely
aggregates or fragments.
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Because storage conditions may affect EV characterization, MISEV guidelines indicate
the importance of describing storage conditions such as storage container, temperature, buffer,
freeze-thaw cycles of biofluid and EVs, etc. (Théry et al., 2018). It was previously found even
that storage of EVs for 2 h at 4°C decreased the viability of the exosome population, but the
change in size was not measured (Zonneveld et al., 2014). The timecourse experiment (Figure 44) represents storage-induced changes in diameter starting from freshly isolated EVs measured
over the course of 10 days. The average diameter of EVs measured by DLS increased over time
after isolation and storage. This may indicate swelling and enlargement of EVs, or aggregation of
particles. Therefore, when performing studies to determine the relation between structure and
function, it may be advantageous to use EVs immediately after isolation.
For protein-based verification of EV isolation, MISEV guidelines stipulate that at least
one type of protein in two broad categories should be positively identified and the absence of one
negative marker indicated. These categories include transmembrane or GPI-anchored proteins,
such as the tetraspanins CD63 and CD81, and EV-recovered cytosolic proteins such as ALIX
and flotillins-1 and 2. To verify the absence of non-EV isolated co-structures, markers such as
albumin can be used (Théry et al., 2018). The antibody array (Figure 4-5) verified that human
milk EVs isolated were positive for proteins in the tetraspanin and EV-recovered cytosolic
proteins category, and also negative for cellular contamination marker.
The amount of exosomal protein has been used as a means of EV quantification (Kim,
Tan, & Lubman, 2015). Considering that the average protein concentration measured in EVs was
5.08 mg/dL, EV protein comprises ~0.42% of total protein from mature human milk, assuming
the protein concentration of mature human milk is ~1,200 mg/dL (Ballard & Morrow, 2013).
However, it should be noted that protein quantification with biofluids such as human milk may
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not be a consistent and reliable method of quantification due to the presence of co-isolated
molecules. Therefore, we reported the total fatty acid concentration of human milk EVs (Figure
4-6). Based on the assumption that fat content of human milk is primarily in the form of
triglyceride, we estimated that EV fatty acids are ~0.8% of total fatty acids in mature human
milk (Ballard & Morrow, 2013).
We compared fatty acid quantification among EVs isolated from human milk with
different volumes of reagent, use of size exclusion filter, and with or without column affinity
purification. We suggest a supernatant-to-precipitation reagent ratio of 5:1 for optimal yield of
EVs to quantify fatty acids. We also suggest filtration of milk by size exclusion after defatting to
remove non-EV artifacts such as casein and cellular debris. However, it is unclear whether
column affinity purification after EV isolation performs similarly to size exclusion filtration of
milk supernatant prior to EV isolation. Although fatty acid quantification was similar after each
method, it is unknown if filtration and purification result in differences in the EV populations
isolated.
The present method of isolating EVs from human milk fulfills the MISEV criteria by
characterizing the EVs with quantitative and qualitative methods, confirming the presence of
characteristic EV markers, and confirming (Figure 4-5) the absence of non-EV components. The
application of this isolation method extends beyond the applications detailed in our manuscript.
The ability to successfully isolate EVs from small volumes of human milk can be applied to
miRNA isolation, proteomics, lipidomics, and functional in vitro assays.
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Conclusions
EVs were successfully isolated from human milk using a precipitation reagent. The method
yielded 8.9 × 109 ± 1.1 × 109 EV particles/mL of human milk. Protein and fatty acid
concentration of EVs in human milk were determined and the percentage of fatty acids and
protein in EVs relative to the whole milk were ~0.8% and ~0.42%, respectively. The method
presented is consistent and reliable for isolating, quantifying, and characterizing human milk
EVs for research and clinical purposes and in continuing to understand the human milk food
matrix. As a dynamic food and biofluid, future study may elucidate how EVs vary over i) early,
transitional and mature milk production periods, ii) course of lactation (fore vs. hind milk), and
iii) time-of-day variation. This method can be used to elucidate the role of human milk EVs in
neonatal health and immune system development, and for applications of formula and human
milk fortifier production.
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5. Fatty acids and EVs in human milk: Global discussion, conclusions, and
future work
Discussion
The overarching goals of this project were to correlate the fatty acid composition of
human milk and human milk EVs to infant development (Cognitive, Behavioral, and Motor)
outcomes reported by the Bayley Scales of Infant Development (BSID-III). However, the latter
objective was not feasible due to the lack of a suitable method to isolate EVs from small volumes
(<2 mL) of human milk. Thus, in order to carry out this hypothesis, the following objectives
were investigated instead: i) whether essential fatty acids correlated to BSID-III developmental
outcomes, and ii) whether there was a consistent method to isolate EVs from human milk. Both
objectives investigated in the present study were novel and resulted in novel research findings.
Specifically, it was found that ARA was inversely correlated to Bayley Cognitive Composite
scores, and EVs were able to be successfully isolated from human milk. EV isolation was also
validated according to the criteria of the International Society of Extracellular Vesicles (Théry et
al., 2018).
The present research is significant, because it represents the possibility of implementing
modifiable changes that can confer long term benefits. Many predictors of long term health, such
as genetics and socioeconomic status cannot be modified. However, nutrition is unique in that it
is a modifiable factor that can be controlled from infancy onwards. Although public health
disparities may prevent lactating mothers from accessing recommended nutrition, the present
research also pertains to the optimization of commercial infant formula products. Even if parents
are unable to provide their child with human milk, or lactating mothers are unable to follow
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nutritional guidelines, associating fatty acids and EVs with infant development will facilitate
product development for commercial infant formula products that confer the developmental
benefits associated with human milk.
Bioactive compounds in human milk, such as the milk fat globule membrane (MFGM)
have already been extensively studied in relation to infant nutrition. MFGM acts as a natural
emulsifier to prevent the fat molecules from coalescing in milk and against enzymatic action
(Singh, 2006). Various nutritional benefits, such as the reduction of necrotizing enterocolitis and
neonatal gut maturation have been associated with MFGM (Dewettinck et al., 2008). MFGM
have already been extensively characterized in human milk with respect to the lipid
(Demmelmair, Koletzko, & panel, 2018), and protein (Yang et al., 2020) composition, and have
even been incorporated into infant formula (Gallier et al., 2015). However, the relation between
the composition of other bioactive compounds in human milk, such as EVs, and infant
development remains unknown. Now that a method to isolate EVs from human milk has been
validated, this gap in knowledge can be addressed. A consistent method of EV isolation will
permit structure and functional analyses, which could eventually facilitate the incorporation of
EVs in infant formula products. Overall, the objectives of the present study were met. Clinical
research can incorporate this knowledge into product development and nutritional
recommendations for babies and mothers.

66

Conclusions and Future Work
The present study examined the relation between bioactive components in human milk
and infant developmental outcomes. It was determined if i) essential fatty acids correlated to
BSID-III developmental outcomes, and ii) whether there was a consistent method to isolate EVs
from human milk. It was found that ARA was inversely correlated with cognitive outcomes at 12
months of age. EVs were successfully isolated from a small (< 2 mL) volume of human milk
using an adapted precipitation method, and were subsequently qualitatively and quantitatively
characterized. Overall, this work can inform education initiatives to promote optimal infant
health and development outcomes through maternal nutrition. Future work could also extend
upon the present study to examine EV composition. With the optimization of a suitable isolation
method, structural and functional studies can now be performed to assess whether the fatty acid
composition in EV-enriched fractions of human milk differs significantly from the whole human
milk, and whether fatty acid composition of EVs relates to infant developmental outcomes.
Future work could also consider whether maternal FADS genotype correlates to fatty acid
composition in human milk and human milk EVs.
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